Publication
Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration-Resistant Prostate Cancer.
Meghana Yellanki, Jennifer La, Danne C Elbers, Nhan V Do, Channing J Paller, Nathanael R Fillmore, Martin W Schoen
The ProstateSep 17, 2026PMID 42752817doi:10.1002/pros.70247 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration-resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.